Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

NantHealth unveils next-generation tool for blood-based tumor profiling and quantitative monitoring

Published 04 June 2018

NantHealth, a member of the NantWorks ecosystem of companies, has unveiled next-generation tool for blood-based tumor profiling and quantitative monitoring, Liquid GPS.

NantHealth chose the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting to showcase the potential of Liquid GPS — a blood-based molecular test that provides oncologists with a powerful tool to continuously monitor and profile tumors, an approach that is less invasive than a traditional biopsy.

Liquid GPS™ expands upon NantHealth’s molecular analysis portfolio of products — which includes the tissue-based GPS Cancer ™ solution. Liquid GPS offers sophisticated analysis tools — looking beyond cfDNA to cfRNA.

This technology allows more comprehensive profiling and trending of biomarkers that can’t be assessed by cfDNA alone. As a result, Liquid GPS offers a richer portrait of a patient’s condition and offers more therapeutic targets, such as chemotherapy and immunotherapy, than a typical liquid biopsy.

NantHealth CEO Dr. Patrick Soon-Shiong said: “We believe the development of Liquid GPS is important to our broader vision for fighting cancer from a biological, rather than an anatomical perspective.

“This test is a non-invasive way to achieve molecular insights that could help shape treatment and provide the oncologist and patients real-time information on the status of the cancer. This work builds on what NantHealth has already done with GPS Cancer as we focus on successfully analyzing and treating cancer at the molecular level.”

NantHealth is a next-generation, evidence-base, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses.

NantHealth’s focused portfolio exemplifies its unique systems-based approach to personalized healthcare and integrates novel analysis with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine.

Source: Company Press Release